<DOC>
	<DOCNO>NCT01469039</DOCNO>
	<brief_summary>The study determine efficacy ALKS 9072 ( also know aripiprazole lauroxil ALKS 9070 ) treatment schizophrenia subject experience acute exacerbation .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ALKS 9072 ( Also Known Aripiprazole Lauroxil , ALKS 9070 , ARISTADA ) Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Diagnosis schizophrenia accord DSMIVTR criterion Has able achieve outpatient status 3 month past year Body mass index ( BMI ) 18.5 40.0 kg/m2 ( inclusive ) Resides stable living situation Willing able confine inpatient study unit 2 week longer History poor inadequate clinical response treatment aripiprazole History treatment resistance Known suspect intolerance , allergy , hypersensitivity aripiprazole , ingredient , antipsychotic agent , INTRALIPID ( include peanut , soy , egg , glycerol ) Diagnosis current substance dependence ( include alcohol ) Pregnant , lactating , breastfeed Receipt antipsychotic medication IM injection within 60 day Screening Current involuntary hospitalization incarceration Hospitalized 30 day 90 day Screening Additional inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>ALKS 9072</keyword>
	<keyword>ALKS 9070</keyword>
	<keyword>aripiprazole lauroxil</keyword>
</DOC>